The Cooper Companies, Inc. (NASDAQ:COO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have been given a consensus rating of “Moderate Buy” by the twelve brokerages that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $111.78.

COO has been the subject of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $115.00 price target on shares of Cooper Companies in a report on Wednesday, July 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Friday, May 31st. Citigroup lifted their price target on shares of Cooper Companies from $108.00 to $116.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Robert W. Baird upped their price objective on shares of Cooper Companies from $116.00 to $118.00 and gave the company an “outperform” rating in a research report on Friday, May 31st. Finally, Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and lifted their target price for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th.

Cooper Companies Stock Performance

Shares of COO stock opened at $91.47 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.14 and a debt-to-equity ratio of 0.34. The company has a market cap of $18.21 billion, a PE ratio of 53.73, a P/E/G ratio of 2.25 and a beta of 0.98. The company’s fifty day simple moving average is $91.72 and its 200-day simple moving average is $94.32. Cooper Companies has a 52 week low of $75.93 and a 52 week high of $104.07.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, May 30th. The medical device company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.83 by $0.02. Cooper Companies had a return on equity of 8.87% and a net margin of 9.11%. The company had revenue of $942.60 million for the quarter, compared to analyst estimates of $948.07 million. During the same period last year, the company posted $0.77 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Cooper Companies will post 3.57 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Lipe & Dalton lifted its position in shares of Cooper Companies by 0.9% in the 4th quarter. Lipe & Dalton now owns 3,360 shares of the medical device company’s stock worth $1,272,000 after buying an additional 30 shares during the last quarter. WD Rutherford LLC lifted its holdings in Cooper Companies by 0.4% in the fourth quarter. WD Rutherford LLC now owns 9,126 shares of the medical device company’s stock worth $3,541,000 after acquiring an additional 33 shares during the last quarter. Blue Trust Inc. boosted its stake in Cooper Companies by 54.8% in the fourth quarter. Blue Trust Inc. now owns 96 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 34 shares during the period. Franklin Resources Inc. grew its holdings in shares of Cooper Companies by 1.2% during the fourth quarter. Franklin Resources Inc. now owns 3,401 shares of the medical device company’s stock valued at $1,287,000 after purchasing an additional 41 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its position in shares of Cooper Companies by 30.4% during the 4th quarter. Venturi Wealth Management LLC now owns 180 shares of the medical device company’s stock worth $68,000 after purchasing an additional 42 shares during the period. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.